SCLN SciClone Pharmaceuticals Inc.

SCICLONE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout

WILMINGTON, Del.--(BUSINESS WIRE)--

Rigrodsky & Long, P.A.:

  • Do you own shares of SciClone Pharmaceuticals, Inc. (NASDAQ GS: SCLN)?
  • Did you purchase any of your shares prior to June 8, 2017?
  • Do you think the proposed buyout is fair?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of SciClone Pharmaceuticals, Inc. (“SciClone” or the “Company”) (NASDAQ GS: SCLN) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by a consortium consisting of entities affiliated with GL Capital Management GP Limited ("GL Capital"), Bank of China Group Investment Limited ("BOCGI"), CDH Investments, Ascendent Capital Partners and Boying (collectively, the "Buyer Consortium") in a transaction valued at approximately $605 million. Under the terms of the agreement, shareholders of SciClone will receive $11.18 in cash for each share of SciClone common stock.

Click here to learn more: http://rigrodskylong.com/investigations/sciclone-pharmaceuticals-inc-scln.

If you own common stock of SciClone and purchased any shares before June 8, 2017, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail at [email protected]; or at: http://rigrodskylong.com/investigations/sciclone-pharmaceuticals-inc-scln.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities fraud, shareholder corporate, and shareholder derivative litigation on behalf of shareholders in state and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

EN
13/06/2017

Underlying

SCLNSciClone Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SciClone Pharmaceuticals Inc.

Free Trial
SCLN SciClone Pharma...

Five Directors sold after exercising options/sold 728,187 shares at 11...

Five Directors at Sciclone Pharmaceuticals Inc sold after exercising options/sold 728,187 shares at 11.180USD. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the c...

SCLN SCICLONE PHARMACEUTICALS INC.
10/17/17 October 17, 2017 1 EN
 PRESS RELEASE
Free
SCLN SciClone Pharma...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of SciC...

NEW YORK--(BUSINESS WIRE)-- Levi & Korsinsky, LLP has filed a class action lawsuit in the United States District Court for the Northern District of California on behalf of current stockholders of SciClone Pharmaceuticals, Inc. (“SciClone” or the “Company”) (NASDAQ:SCLN) in connection with the planned acquisition of the company by affiliates of GL Capital Management GP Limited, Bank of China Group Investment Limited, CDH Investments, Ascendent Capital Partners, and Boying Investments Limited (the “Consortium”). On June 8, 2017...

August 29, 2017 1 EN
 PRESS RELEASE
Free
SCLN SciClone Pharma...

INVESTOR ALERT: Brower Piven Commences an Investigation into the Propo...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) (“SciClone” or the “Company”) relating to the proposed buyout of SciClone by a consortium consisting of entities affiliated with GL Capital Management GP Limited, Bank of China Group Investment Limited, CDH Investments, Ascendent Capital Partner...

June 19, 2017 1 EN
 PRESS RELEASE
Free
SCLN SciClone Pharma...

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investig...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) stock prior to June 8, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of SciClone to a consortium led by GL Capital Management GP Limited for $11.18 per share. To learn more about the action and your rights, go to: http://www.zlkdocs.com/SCLN-Info-Request...

June 15, 2017 1 EN
 PRESS RELEASE
Free
SCLN SciClone Pharma...

SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Pr...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) (“SciClone” or the “Company”) relating to the proposed buyout of SciClone by a consortium consisting of entities affiliated with GL Capital Management GP Limited, Bank of China Group Investment Limited, CDH Investments, Ascendent Capital Partner...

June 13, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch